Stansberry's 'Sam Altman Hidden Project' — The Medical AI Pitch Behind the $367 Trillion Claim

The Hook

Stansberry’s latest SIR (Stansberry Investment Advisory) presentation opens the way these promos always do: with a name you already know, and an exit-intent modal that begs you to stay. “Wait. Sam Altman’s Next Venture Is Already Live.” The subheadline escalates fast: “Meet Sam Altman’s Hidden Project… That’s 10,000 Times Faster Than Human PhDs.” And then the kicker, the line that does the real work: “At test sites across America, the staff would go to prison if they told you what they’ve seen.”

That last sentence is doing a lot. It takes a confidentiality agreement, which is a civil contract, and reframes it as a criminal statute, which carries prison time. The effect is a “forbidden knowledge” frame: you, the viewer, are being let in on something other people aren’t allowed to say. It’s a powerful device, and it primes you to believe whatever comes next.

The Big Claim

The headline promise is that Sam Altman, the CEO of OpenAI, is the “secret early backer” of a “new form of AI” that works “10,000 times faster than the smartest human PhDs.” The secondary claims spiral upward from there:

• The AI “could change what it means to be human.”
• It could “ignite a boom in the stock market like nothing we’ve ever seen before.”
• It “could soon be worth $1 million per American.”
• The venture could be worth “$367 trillion” (per the accompanying ad copy).
• “Jeff Bezos, Peter Thiel, and Elon Musk have all put their own money behind it.”
• “MIT has confirmed” the technology.

The numbers here are the tell. A “$1 million per American” claim, applied to roughly 330 million people, implies a market of about $330 trillion. The “$367 trillion” figure in the ad copy sits in the same ballpark. Global GDP is roughly $110 trillion. So this promo is asking you to believe in a single technology worth three times everything the world produces in a year.

The Mechanism

The mechanism is “medical AI,” AI applied to drug discovery and medical research, and it’s the one thing in this promo with a real foundation. AI genuinely is being used to find new medicines. Google DeepMind’s AlphaFold transformed protein-structure prediction. Companies like Insilico Medicine, Exscientia, and Recursion Pharmaceuticals run real AI drug-discovery programs. We covered one of these recently in our teardown of Angel Publishing’s “Quantum Quake”, which named Recursion (RXRX) as its reveal, and the underlying science, AI screening molecules faster than human chemists, is not science fiction.

Altman’s personal investment record in this space is also real, though the promo stretches it. He has backed Helion Energy and Retro Biosciences, among others, and he clearly believes AI will reshape biology. Bezos, Thiel, and Musk all invest in AI. The “four billionaires backed this specific project” framing, however, is where the promo leaves reality: the page copy offers no evidence that all four have backed the specific “hidden project” being teased, as opposed to AI in general.

The “why hasn’t everyone heard about this” answer, that it’s still secret, is also doing a lot of work. The tech is “already live” at “test sites across America,” but you can’t verify any of it, because the staff “would go to prison.” That’s not secrecy; that’s unfalsifiability.

The Real Pick

No ticker is revealed in this promo. The page copy teases “one small group of stocks” that will “go soaring,” and stops there. The full video transcript was not retrievable, and the actual names sit behind the Stansberry order form.

The clues point toward medical AI and AI drug discovery. The candidates the analysis surfaced:

Recursion is the purest AI-drug-discovery name here, and it’s the same company Angel Publishing teed up in its Quantum Quake promo, which tells you how crowded this theme has become. At roughly $3.30, RXRX is a clinical-stage biotech with a real AI platform and the balance-sheet risk that comes with it. Veeva at roughly $242 is a very different animal, a profitable life-sciences software business rather than a clinical-stage biotech, but it shows up in “medical AI” screeners because of its data moat.

As with the Altimetry promo, the honest read is that the tickers are the carrot, and the subscription is the sale. You can’t act on a “small group of stocks” that is never named.

Does the Math Check Out?

“$367 trillion.” No credible market sizing puts medical AI anywhere near this. Even the most bullish analyst projections for the entire healthcare AI market run in the low hundreds of billions over the next decade. A $367 trillion figure is more than three times global GDP. It’s not an estimate; it’s a number chosen to be too big to argue with.

“10,000 times faster than human PhDs.” Faster at what? Over what benchmark? Measured by whom? A claim like this only means something with a task and a methodology attached. Without them, it’s a slogan. AI can screen molecular libraries faster than a human chemist can physically do it, but “10,000 times” is a precision that implies a measurement that is never provided.

“MIT has confirmed.” Confirmed what? Which lab, which paper, which researcher? MIT does a lot of AI work, but the promo cites no study, no department, no author. Authority transfer works by borrowing a name without specifying the claim, and that’s exactly what’s happening here.

“Staff would go to prison.” NDAs are contracts, not criminal law. Violating one exposes you to a lawsuit, not a prison sentence. This is a dramatic flourish, and it’s worth flagging because it’s the kind of line that makes the whole promo feel like a thriller rather than a financial pitch.

“Worth $1 million per American.” Divide $330 trillion by 330 million and you get the circular logic: the per-capita figure is just the total figure restated. It’s designed to make the number feel personal, your share of the fortune, without adding any information.

What They Got Right

1. AI drug discovery is a genuine, growing field. AlphaFold, Insilico, Recursion, Exscientia, this is real science making real progress, and the investment theme has legs.
2. Altman’s interest in biology is real and documented. His investments in longevity and biotech AI are a matter of public record, and the promo is correct that a serious figure takes the space seriously.
3. Billionaire AI investment is a fact. Musk founded xAI, Thiel was an early OpenAI backer, Bezos is a major AI investor. The names are real, even if the “all four backed this one project” framing is not.
4. The medical AI angle is at least differentiated. In a field crowded with AI-infrastructure promos, a drug-discovery pitch is a genuinely different lens on the same underlying trend.

What They Got Wrong

1. The $367 trillion figure is indefensible. It’s more than triple global GDP, has no source, and serves only to short-circuit the viewer’s skepticism.
2. “10,000 times faster” is a slogan, not a claim. No task, no benchmark, no measurement. It can’t be verified, and it’s probably not meant to be.
3. “Staff would go to prison” is a legal fiction. NDAs are civil, not criminal, and the line exists to manufacture a secrecy mystique.
4. The “four billionaires backed this” framing is unverified. Real investors, real AI interest, but no evidence they all backed this specific project. The promo relies on you not asking which one.
5. The ticker is never named. The entire pitch is a tease. The free content delivers no actionable information.

The Verdict

The medical AI theme is real, and if you want exposure to it, the public options are genuinely interesting. Recursion and Veeva both sit at the intersection of AI and biology, and the science behind AI drug discovery is advancing faster than the headlines suggest.

But this promo isn’t selling you exposure to medical AI. It’s selling you a subscription, and it’s doing it with the biggest number in the financial-newsletter business this year, $367 trillion, plus a “prison” line borrowed from a spy thriller. The gap between the real, interesting trend underneath and the hyperbolic wrapper on top is the widest of the three promos we vetted this week.

If you’re curious about AI in biology, you don’t need to subscribe to Stansberry to learn about it. The companies are public, the research is published, and the trend is visible to anyone who looks. The promo’s real message is that you need to pay to be let in on a secret that, on inspection, isn’t a secret at all, just a number too big to be true. We’ve looked at how Stansberry’s promos are typically constructed, and this one fits the pattern.

This is not financial advice. NewsletterVetter has no position in any stock mentioned.